Advertisement

Topics

Novartis pulls off surprise success in cardiovascular risk

04:54 EDT 22 Jun 2017 | Pharmafile

Novartis has posted positive news from the Cantos clinical trial study that saw its drug, Canakinumab, pull of a surprise result to reduce the risk of cardiovascular issues. The reason the results were not expected is due to the method of action of the drug, which reduces inflammation.

read more

Original Article: Novartis pulls off surprise success in cardiovascular risk

NEXT ARTICLE

More From BioPortfolio on "Novartis pulls off surprise success in cardiovascular risk"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...